|
|
| Line 1: |
Line 1: |
| __NOTOC__ | | __NOTOC__ |
|
| |
| {{Cilostazol}} | | {{Cilostazol}} |
| {{CMG}}; {{AE}} {{AZ}} | | {{CMG}}; {{AE}} {{AZ}} |
|
| |
|
| ==Description==
| |
|
| |
| PLETAL (cilostazol) is a quinolinone derivative that inhibits cellular phosphodiesterase (more specific for phosphodiesterase III). The empirical formula of cilostazol is C20H27N5O2, and its molecular weight is 369.46. Cilostazol is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone, CAS-73963-72-1.
| |
|
| |
| The structural formula is:
| |
| {|
| |
|
| |
| |[[File:Cilostazolstructure.JPG|400px|thumb]]
| |
|
| |
| |}
| |
|
| |
| Cilostazol occurs as white to off-white crystals or as a crystalline powder that is slightly soluble in methanol and ethanol, and is practically insoluble in water, 0.1 N HCl, and 0.1 N NaOH.
| |
|
| |
|
| PLETAL (cilostazol) tablets for oral administration are available in 50 mg triangular and 100 mg round, white debossed tablets. Each tablet, in addition to the active ingredient, contains the following inactive ingredients: carboxymethylcellulose calcium, corn starch, hydroxypropyl methylcellulose 2910, magnesium stearate, and microcrystalline cellulose.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PLETAL (CILOSTAZOL) TABLET [OTSUKA AMERICA PHARMACEUTICAL, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24d75b58-bafb-4440-b8d7-4f4079c08b0b | publisher = | date = | accessdate = }}</ref>
| |
|
| |
|
| | <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PLETAL (CILOSTAZOL) TABLET [OTSUKA AMERICA PHARMACEUTICAL, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24d75b58-bafb-4440-b8d7-4f4079c08b0b | publisher = | date = | accessdate = }}</ref> |
| ==References== | | ==References== |
| {{Reflist}} | | {{Reflist}} |
Revision as of 22:01, 30 January 2014